Before joining Moffitt in 1995, he was an associate professor at the University of Louisville in the Department of Biochemistry and Medicine. Daniel’s research interests include the mechanism of drug resistance to common anti-tumor agents for patients with hematologic malignancies, small cell lung cancer, malignant melanoma and rectal carcinoma.
He is co-chair of the National Cancer Institute (NCI) Investigational Drug Steering Committee, a member of the NCI Operational Efficiency Work Group, and has served as chair of the American Cancer Society Cancer Drug Development Peer Review Committee. In addition, he is a grant reviewer for the National Institutes of Health and a manuscript reviewer for 19 different peer-reviewed publications. Daniel has received numerous professional awards and has been named one of America’s Best Doctors for nine years in a row.
Daniel received his bachelor’s degree and medical degree, followed by a master’s degree in biochemistry from the University of Louisville, KY. He completed a fellowship in hematology/oncology from the University of Florida.